A new clinical trial, co-led by endocrinologist and diabetes expert John Buse, MD, PhD, and interventional cardiologist Matthew Cavender, MD, MPH, at the UNC School of Medicine has shown that the oral form of semaglutide can significantly reduce cardiovascular events in people with type 2 diabetes and atherosclerotic cardiovascular disease, and/or chronic kidney disease
The cornerstone of management is maintaining adequate hydration
These areas were selected because they have enough subcutaneous fat for safe, effective medication absorption while being relatively accessible and comfortable
Moreover, adults typically have greater healthcare access and are more proactive in seeking weight loss treatments compared to younger populations
If youre looking for a revolutionary solution to your weight loss journey, consider semaglutide therapy at Denver, CO by Beyond Stem Cells
[2] Jastreboff AM, et al